Skip to main content

Table 1 Clinical characteristics and treatment of 216 patients with multiple myeloma

From: Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience

Characteristics IgD subtype Non-IgD subtypes P value
Cases, n 13 203  
Age [years; median (range)] 52 (44–66) 60 (24–82) 0.028
Sex [cases (%)] 0.782
 Male 8 (61.5) 117 (57.3)  
 Female 5 (38.5) 86 (42.7)  
Hemoglobin [g/L; mean (range)] 73 (44–108) 90 (40–107) 0.011
Platelets < 100 × 109/L [cases (%)] 4 (30.8) 32 (15.8) 0.306
Light chain type [cases (%)] 0.006
 κ 1 (7.7) 104 (51.2)  
 λ 12 (92.3) 99 (48.8)  
Creatinine > 2 mg/dL [cases (%)] 9 (69.2) 47 (23.2) < 0.001
β2M [mg/L; mean (range)] 10 (2.57–16.50) 5.16 (1.45–19.40) 0.001
Bone lesion [cases (%)] 10 (76.9) 170 (83.7) 0.459
Hypercalcemia [cases (%)] 3(23.1) 14 (6.9) 0.117
Urine protein (g/L) 3.20 (0.15–19.69) 1.30 (0.10–26.10) 0.196
LDH > 250 U/L [cases (%)] 7 (53.8) 37 (18.2) 0.002
ISS stage [cases (%)] 0.002
 I 0 41 (20.2)  
 II 0 58 (28.6)  
 III 13 (100.0) 104 (50.2)  
Induction therapy [cases (%)] 0.080
 IMiD-based regimens 4 (30.8) 121(59.6)  
 Bortezomib-based regimens 9 (69.2) 82 (40.4)  
Final response [cases (%)] 0.847
 sCR, CR 4 (30.8) 68 (33.5)  
 VGPR 3 (23.1) 80 (39.4)  
 PR 4 (30.8) 43 (20.9)  
 SD plus PD 2 (15.4) 12 (5.8)  
AL amyloidosis [cases (%)] 4 (30.8) 8 (3.9) 0.001
Extramedullary infiltration [cases (%)] 2 (15.4) 57 (28.1) 0.500
  1. IgD immunoglobulin D, β2M β2 microglobulin, LDH lactate dehydrogenase, ISS international staging system, IMiD immunomodulatory drug, sCR strict complete response, CR complete response, VGPR very good partial response, PR partial response, SD stable disease, PD progressive disease, AL amyloidosis amyloid light-chain amyloidosis